SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: WWS who wrote (707)6/10/1999 2:09:00 PM
From: scaram(o)ucheRespond to of 4974
 
Bill:

Adjuvants were a big part of my life, and I was using MPL from the day it was available. Furthermore, a guy who did his grad work in the lab where I did mine was one of the founders of RIBI. I've therefore followed the company and its business plan closely.

I am not impressed by CRXA's move. Next breath..... all of the non-toxic adjuvants are rather weak, IMO, and revenues derived from a mediocre product are still revenues.

There has always been a competition.... not sure that it's all that friendly.... between certain founders of IMNX. I'll go with Dendreon.

Rick



To: WWS who wrote (707)6/10/1999 4:15:00 PM
From: RWReevesRespond to of 4974
 
I spoke with Nils in the early days and certainly thought they had a good prospect. They had really interesting data in horses but damn, if nearly 20 years later they aren't still SOL. I guess if my horse gets cancer I'm all set.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News